IMNN · Imunon, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed May 12, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-20 | Eylward Susan |
General Counsel and Corp Sec |
Sell↓
Filing footnotes — Common Stock (Direct)
Reflects a weighted average sale price of $1.7816 per share, at prices ranging from $1.76 to $1.79 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. |
Common Stock
|
2,150 |
| 2026-07-17 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
3,082 |
| 2026-07-17 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
2,150 |
| 2026-07-17 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
4,907 |
| 2026-07-17 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
4,603 |
| 2026-07-06 | Eylward Susan |
General Counsel and Corp Sec |
Sell↓
|
Common Stock
|
920 |
| 2026-07-02 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
920 |
| 2026-07-02 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
4,410 |
| 2026-07-02 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
2,534 |
| 2026-07-02 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
1,308 |
| 2026-07-01 | Blacher Joshua |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2026-06-29 | Eylward Susan |
General Counsel and Corp Sec |
Sell↓
Filing footnotes — Common Stock (Direct)
Reflects a weighted average sale price of $1.752 per share, at prices ranging from $1.73 to $1.80 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price. |
Common Stock
|
11,800 |
| 2026-06-25 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for 50% of 2025 annual cash bonus |
Common Stock
|
42,519 |
| 2026-06-25 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for 50% of 2025 annual cash bonus |
Common Stock
|
14,696 |
| 2026-06-25 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for 50% of 2025 annual cash bonus |
Common Stock
|
21,896 |
| 2026-06-25 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for 50% of 2025 annual cash bonus |
Common Stock
|
67,150 |
| 2026-06-18 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
1,803 |
| 2026-06-18 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
4,629 |
| 2026-06-05 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
4,089 |
| 2026-06-05 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
1,593 |
| 2026-05-22 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of base salary |
Common Stock
|
1,491 |
| 2026-05-22 | Pellizzari Christine A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
5,557 |
| 2026-05-22 | Braun Donald P |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
5,011 |
| 2026-05-22 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for base salary |
Common Stock
|
3,484 |
| 2026-05-22 | Fritz Frederick J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees. |
Common Stock
|
10,330 |
| 2026-05-22 | Dentzer James E |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
11,148 |
| 2026-01-02 | Fritz Frederick J. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
5,892 |
| 2026-01-02 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
43,821 |
| 2026-01-02 | Bragg Kimberly |
CFO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
9,050 |
| 2026-01-02 | Braun Donald P |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
5,881 |
| 2026-01-02 | Faller Douglas Vincent |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
12,667 |
| 2026-01-02 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
56,187 |
| 2026-01-02 | Pellizzari Christine A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
4,827 |
| 2026-01-02 | Dentzer James E |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
4,405 |
| 2026-01-02 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
8,251 |
| 2026-01-02 | Anwer Khursheed |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
15,736 |
| 2025-09-06 | Lindborg Stacy |
Director, President and CEO |
Convert↓
Filing footnotes — Restricted Stock (Direct)
Each restricted stock share represents a contingent right to receive one share of Imunon, Inc.'s common stock. On September 6, 2024, Ms. Lindborg received restricted stock representing 1,667 shares (as adjusted for the reverse stock split) subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock shares vest, the vested shares are automatically converted to vested common stock on a one-for-one basis on the vesting date. |
Restricted Stock
|
1,667 |
| 2025-09-06 | Lindborg Stacy |
Director, President and CEO |
Convert↑
Filing footnotes — Common Stock (Direct)
Acquisition of common stock resulting from vesting of 100% of the restricted stock granted to Ms. Lindborg on September 6, 2024. |
Common Stock
|
1,667 |
| 2025-08-04 | Braun Donald P |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
2,040 |
| 2025-08-04 | Fritz Frederick J. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of grant. The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
250 |
| 2025-08-04 | Pellizzari Christine A |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
2,248 |
| 2025-08-04 | Bragg Kimberly |
CFO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
667 |
| 2025-08-04 | Lindborg Stacy |
Director, President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
5,000 |
| 2025-08-04 | Pellizzari Christine A |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of grant. The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
250 |
| 2025-08-04 | Eylward Susan |
General Counsel and Corp Sec |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
417 |
| 2025-08-04 | Fritz Frederick J. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees. |
Common Stock
|
3,161 |
| 2025-08-04 | Dentzer James E |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Stock granted in lieu of cash for portion of board fees |
Common Stock
|
3,318 |
| 2025-08-04 | Tardugno Michael H |
Director, Executive Chairman of Board |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
1,667 |
| 2025-08-04 | Braun Donald P |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of grant. The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
250 |
| 2025-08-04 | Anwer Khursheed |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents the closing price of Imunon, Inc. Common Stock on the date of the grant The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. |
Stock Option (Right to Buy)
|
1,667 |